Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
तुलना करने के लिए मीट्रिक्स | CLNN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCLNNपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.6x | −1.7x | −0.5x | |
PEG अनुपात | −0.04 | 0.03 | 0.00 | |
क़ीमत/बुक | −3.9x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 226.2x | 194.5x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 180.8% | 46.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.5% | 6.4% | अनलॉक करें |